Press Release – New York, NY – April 19, 2022 – Sichenzia Ross Ference LLP announced today that it represented Sharps Technology, Inc. (Nasdaq: STSS and STSSW), an innovative medical device company offering patented, best-in-class, single use smart safety syringe products, in its initial public offering of 3,750,000 units at a public offering price of $4.25 per unit, each consisting of one share of common stock and two warrants to purchase one share of common stock. The gross proceeds from the offering were approximately $16 million, before deducting underwriting discounts, commissions and offering expenses.
The Sichenzia Ross Ference LLP team was led by partners Arthur Marcus and Jeff Cahlon, and associate Michael Blane.
SRFC is a full-service law firm with nationally recognized corporate, securities, and litigation practices that provides experienced representation in all matters involving the securities industry. In addition to handling routine to complex commercial matters, SRFC’s renowned litigation and regulatory department specializes in defending broker-dealers, registered persons, public and private corporations, and individuals in investigations and enforcement proceedings before the SEC, FINRA, and other regulatory bodies, as well as litigations and arbitrations across all forums in the securities industry, including class action lawsuits, shareholder derivative actions, and matters involving allegations of fraud, misrepresentation or other securities violations.
Latest posts by Sichenzia Ross Ference Carmel LLP (see all)
- Sichenzia Ross Ference Carmel LLP Represents BriaCell Therapeutics in $15 Million Public Offering - July 16, 2025
- Sichenzia Ross Ference Carmel LLP Represents 60 Degrees Pharmaceuticals in Public Offering of Up to $10 Million - July 15, 2025
- Sichenzia Ross Ference Carmel LLP Represents Viewbix in $4.5 Million Private Placement - July 15, 2025
